title: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
authors.affiliation: 1 Mayo Clinic Jacksonville, Florida.
authors.forename: Charles D
authors.initials: CD
authors.lastname: Burger
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D065128:Endothelin Receptor Antagonists / Q000627:therapeutic use*; D011464:Epoprostenol / Q000031:analogs & derivatives*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D011720:Pyrazoles; D011743:Pyrimidines; D013449:Sulfonamides; D011464:Epoprostenol